AU2016257023B2 - Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers - Google Patents

Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers Download PDF

Info

Publication number
AU2016257023B2
AU2016257023B2 AU2016257023A AU2016257023A AU2016257023B2 AU 2016257023 B2 AU2016257023 B2 AU 2016257023B2 AU 2016257023 A AU2016257023 A AU 2016257023A AU 2016257023 A AU2016257023 A AU 2016257023A AU 2016257023 B2 AU2016257023 B2 AU 2016257023B2
Authority
AU
Australia
Prior art keywords
ifny
patients
hlh
seq
infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016257023A
Other languages
English (en)
Other versions
AU2016257023A1 (en
Inventor
Fabrizio DE BENEDETTI
Cristina De Min
Walter Ferlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AG
Original Assignee
Swedish Orphan Biovitrum AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum AG filed Critical Swedish Orphan Biovitrum AG
Publication of AU2016257023A1 publication Critical patent/AU2016257023A1/en
Assigned to SWEDISH ORPHAN BIOVITRUM AG reassignment SWEDISH ORPHAN BIOVITRUM AG Request for Assignment Assignors: NOVIMMUNE SA
Application granted granted Critical
Publication of AU2016257023B2 publication Critical patent/AU2016257023B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2016257023A 2015-05-07 2016-05-09 Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers Active AU2016257023B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562158153P 2015-05-07 2015-05-07
US62/158,153 2015-05-07
US201562221393P 2015-09-21 2015-09-21
US62/221,393 2015-09-21
US201562246949P 2015-10-27 2015-10-27
US62/246,949 2015-10-27
PCT/EP2016/060360 WO2016177913A1 (en) 2015-05-07 2016-05-09 Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers

Publications (2)

Publication Number Publication Date
AU2016257023A1 AU2016257023A1 (en) 2017-11-30
AU2016257023B2 true AU2016257023B2 (en) 2022-06-30

Family

ID=56008603

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016257023A Active AU2016257023B2 (en) 2015-05-07 2016-05-09 Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers

Country Status (13)

Country Link
US (2) US11034760B2 (enExample)
EP (1) EP3292147A1 (enExample)
JP (4) JP2018515493A (enExample)
KR (1) KR20180004254A (enExample)
CN (1) CN107849127A (enExample)
AU (1) AU2016257023B2 (enExample)
BR (1) BR112017023867A2 (enExample)
CA (1) CA2985001A1 (enExample)
EA (1) EA037532B1 (enExample)
IL (3) IL282923B2 (enExample)
MX (3) MX2017014294A (enExample)
SG (1) SG10202108996PA (enExample)
WO (1) WO2016177913A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
CA2985001A1 (en) 2015-05-07 2016-11-10 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
US11840564B2 (en) 2015-06-09 2023-12-12 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
JP2019532970A (ja) * 2016-10-24 2019-11-14 ノビミューン エスアー インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン
CN109164266B (zh) * 2017-11-27 2021-09-24 首都医科大学附属北京友谊医院 细胞因子在区分淋巴瘤相关噬血细胞综合征和淋巴瘤中的应用
WO2019108456A1 (en) * 2017-12-01 2019-06-06 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
EP3762416A4 (en) * 2018-03-09 2021-12-08 Children's Hospital Medical Center COMPOSITIONS AND METHODS OF TREATMENT OF MACROPHAGE ACTIVATION SYNDROME
CN113045655A (zh) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
WO2021185832A1 (en) 2020-03-16 2021-09-23 Swedish Orphan Biovitrum Ag New therapeutic treatment
JP7396213B2 (ja) * 2020-06-22 2023-12-12 Tdk株式会社 データ解析システム、データ解析方法及びデータ解析プログラム
CN115812671B (zh) * 2022-11-17 2024-07-19 青岛大学 帕金森病动物模型的建立方法及其应用
WO2024254401A1 (en) 2023-06-09 2024-12-12 Children's Hospital Medical Center Treatment of stem cell graft failure
CN118266439A (zh) * 2024-04-26 2024-07-02 倍科为(天津)生物技术有限公司 一种斑马鱼继发性噬血细胞综合征模型的构建方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109191A2 (en) * 2005-01-27 2006-10-19 Novimmune S.A. Human anti-interferon gamma antibodies and methods of use thereof
WO2013078378A1 (en) * 2011-11-23 2013-05-30 Amgen Inc. Methods of treatment using an antibody against interferon gamma

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4599306A (en) 1983-04-15 1986-07-08 Amgen Monoclonal antibodies which specifically bind to human immune interferon
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU678429B2 (en) 1992-12-29 1997-05-29 Genentech Inc. Treatment of inflammatory bowel disease with IFN-gamma inhibitors
US20030059428A1 (en) 1993-02-26 2003-03-27 Boris Skurkovich Treatment of autoimmune diseases
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6861056B2 (en) 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
JP2005529152A (ja) 2002-05-17 2005-09-29 プロテイン デザイン ラブス インコーポレイティド 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療
US20040052791A1 (en) 2002-05-22 2004-03-18 Rolf Ehrhardt Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
GB0314461D0 (en) 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
GB0607943D0 (en) 2006-04-21 2006-05-31 Novartis Ag Biomarkers for chronic transplant dysfunction
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
NZ585516A (en) 2007-12-21 2012-07-27 Hoffmann La Roche Anti-cd20 antibody formulation
WO2010042705A1 (en) 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
RU2011140486A (ru) 2009-03-06 2013-04-20 МЕДИММЬЮН, ЭлЭлСи Композиции, содержащие гуманизированные антитела к cd19
CA2783715A1 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
US9220776B2 (en) * 2011-03-31 2015-12-29 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
JPWO2015190378A1 (ja) 2014-06-10 2017-04-20 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定なアダリムマブ水性製剤
US20170360929A1 (en) * 2014-12-23 2017-12-21 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
CA2985001A1 (en) 2015-05-07 2016-11-10 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
JP2019532970A (ja) 2016-10-24 2019-11-14 ノビミューン エスアー インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109191A2 (en) * 2005-01-27 2006-10-19 Novimmune S.A. Human anti-interferon gamma antibodies and methods of use thereof
WO2013078378A1 (en) * 2011-11-23 2013-05-30 Amgen Inc. Methods of treatment using an antibody against interferon gamma

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AIEOP presentation "Plasma levels of IFN-y in hemophagocytic syndrome," November 2013, pages 1-20, available at www.aieop.org/web/wp-content/uploads/2018/02/Giornate-AIEOP-2013.pdf *
Anonymous: "NCT01818492 on 2015_03_08: ClinicalTrials.gov Archive",, First Posted : March 26, 2013, Retrieved online: https://www.clinicaltrials.gov/ct2/show/NCT01818492 [retrieved on 06-06-2021] *
Anonymous: "Novimmune -- NEWS: European Commission awards EUR 6 million FP7 grant to support clinical development of Nl-0501 to 'FIGHT HLH"', 15 October 2012 *
Anonymous: "Novimmune -- NEWS: New drug begins testing as first-line treatment for fatal childhood disease." 16 March 2015 *
Anonymous: "Public summary of opinion on orphan designation Recombinant human anti-interferon gamma monoclonal antibody for the treatment of haemophagocytic lymphohistiocytosis", EMA/COMP/164768/2010, 10 June 2010, Retrieved online. *
Jordan MB, et al. "How I treat hemophagocytic lymphohistiocytosis." Blood. 2011 Oct 13;118(15):4041-52. Epub 2011 Aug 9. *
Jordan MB. et al. " An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder." Blood. 2004 Aug 1;104(3):735-43. Epub 2004 Apr 6. *
Pachlopnik Schmid J, et al. "Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice." EMBO Mol Med. 2009 May;1(2):112-24. *

Also Published As

Publication number Publication date
CA2985001A1 (en) 2016-11-10
JP7685008B2 (ja) 2025-05-28
US20210101972A1 (en) 2021-04-08
US11034760B2 (en) 2021-06-15
BR112017023867A2 (pt) 2018-07-24
JP2025118898A (ja) 2025-08-13
JP2021100943A (ja) 2021-07-08
MX2022001008A (es) 2022-02-22
SG10202108996PA (en) 2021-09-29
EP3292147A1 (en) 2018-03-14
WO2016177913A1 (en) 2016-11-10
IL282923B2 (en) 2023-10-01
EA037532B1 (ru) 2021-04-08
KR20180004254A (ko) 2018-01-10
IL255440A0 (en) 2017-12-31
CN107849127A (zh) 2018-03-27
EA201792447A1 (ru) 2018-05-31
IL282923B1 (en) 2023-06-01
IL255440B (en) 2021-08-31
AU2016257023A1 (en) 2017-11-30
US12275785B2 (en) 2025-04-15
JP2023090964A (ja) 2023-06-29
JP2018515493A (ja) 2018-06-14
MX2024001909A (es) 2024-02-28
US20160326244A1 (en) 2016-11-10
IL282923A (en) 2021-06-30
IL302519A (en) 2023-07-01
MX2017014294A (es) 2018-08-09

Similar Documents

Publication Publication Date Title
US12275785B2 (en) Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
US12297264B2 (en) Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
JP7562074B2 (ja) インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン
Prasad et al. Rheumatoid arthritis: advances in treatment strategies
Pardeo et al. Systemic juvenile idiopathic arthritis: new insights into pathogenesis and cytokine directed therapies
CA2831732C (en) Use of a monoclonal anti-beta7 antibody for treating gastrointestinal inflammatory disorders
WO2020097321A1 (en) Treatment for giant cell arteritis
EA042261B1 (ru) Способы, композиции и режимы дозирования для лечения или профилактики связанных с интерфероном-гамма заболеваний
EA049189B1 (ru) Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров
Byng-Maddick Differential effects of anti-TNF therapies for inflammatory arthritides on immune responses to Mycobacterium tuberculosis

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SWEDISH ORPHAN BIOVITRUM AG

Free format text: FORMER APPLICANT(S): NOVIMMUNE SA

FGA Letters patent sealed or granted (standard patent)